C$0.88 AIDX.TO Healwell AI Inc. (TSX) pre-market 16 Mar 2026: model -18% outlook

AIDX.TO stock trades at C$0.88 in pre-market on 16 Mar 2026, down 2.22% from the previous close. Volume is 268,506 shares versus a 50-day average of 558,510, flagging lighter trading ahead of an earnings release on 19 Mar 2026. Healwell AI Inc. (AIDX.TO) is a Toronto‑listed healthcare AI provider focused on preventative care platforms. This pre-market move follows a mixed technical setup and model projections that point to near-term downside risk while long‑term adoption remains an upside case.

AIDX.TO stock price snapshot and key metrics

Current price is C$0.88 with a day range C$0.88–C$0.92 and year range C$0.58–C$1.81. Market cap is C$247,774,014, shares outstanding 278,397,768, EPS ‑0.23, and reported PE ‑3.87. The 50‑day average is C$0.80 and the 200‑day average is C$1.16, showing the stock sits between short and long trend levels.

AIDX.TO stock technicals and trading signals

Momentum readings show RSI 64.39 and MACD histogram 0.03, indicating positive short‑term momentum but near overbought levels. Average volume is lower at 268,506 versus 558,510 average, which raises the risk of sharp moves around news. ADX of 38.14 signals a strong trend, so earnings could amplify directional movement.

AIDX.TO stock fundamentals and valuation

Healwell AI’s price‑to‑sales is 2.45, price‑to‑book 1.74, current ratio 0.85, and debt‑to‑equity 0.74, reflecting modest leverage and tight liquidity. Trailing free cash flow per share is negative at ‑0.11, and operating cash flow per share is ‑0.10, underlining cash burn risks. These metrics support a cautious valuation stance within the Healthcare sector on the TSX.

Meyka Grade & model forecast for AIDX.TO stock

Meyka AI rates AIDX.TO with a score out of 100: 62.17 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly price of C$0.72, a monthly price of C$0.65, and a yearly price of C$0.40. Compared with the current price C$0.88, the quarterly projection implies ‑18.18% downside; forecasts are model‑based projections and not guarantees.

Catalysts, risks and sector context for AIDX.TO stock

Near‑term catalyst is the earnings announcement on 19 Mar 2026, which could drive volatility and volume. Healwell’s strategic alliance with WELL Health Technologies supports commercialization but execution risk and cash flow remain material risks. Canada’s Healthcare sector has underperformed recently; sector 3‑month performance is weaker, which may pressure AIDX.TO even if product adoption improves.

Practical price targets and scenario planning for AIDX.TO stock

We present scenario targets (not recommendations): conservative C$0.60 (weak earnings / lower adoption), base C$0.72 (model median), optimistic C$1.10 (accelerated contracts and margin improvements). Targets tie to revenue growth, operating cash flow improvements, and a recovery toward the 200‑day average C$1.16 if fundamentals improve.

Final Thoughts

Key takeaway: AIDX.TO stock trades at C$0.88 pre‑market on 16 Mar 2026 with muted volume but clear event risk as earnings approach on 19 Mar 2026. Meyka AI’s forecast model projects a quarterly price of C$0.72, implying ‑18.18% near‑term downside versus the current price; monthly and yearly scenario projections show deeper downside if execution stalls. Financials show EPS ‑0.23, P/S 2.45, and fragile cash flow with free cash flow per share ‑0.11, so liquidity and execution are the dominant risks. Our three‑tier scenario targets (C$0.60 / C$0.72 / C$1.10) map outcomes to earnings and contract progress. Investors focused on AI healthcare should watch the earnings release, volume trends, and any updates to the WELL Health alliance. Meyka AI, an AI‑powered market analysis platform, provides these model projections to inform your research; forecasts are projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.